Transatlantic data burst
April 6, 2022
364,173
10,582
2,612
3.62%
Search the Record
IndexedEvery word spoken in this episode is indexed. Type any phrase to jump straight to the moment it was said.
Type any word or phrase that may have been spoken. Click a result to seek the player to that exact moment.
Try a name, a topic, or a quoted line
Dr John Campbell Episodes Around April 6, 2022
See what was published immediately before and after this episode.
17:42Now PlayingTransatlantic data burst
YouTube Description
as posted by the channelCovid symptom study, another day, another record number of cases
ONS latest
7.56% in England (1 in 13 people)
6.97% in Wales (1 in 14 people)
6.70% in Northern Ireland (1 in 15 people)
8.57% in Scotland (1 in 12 people)
Reinfection
The risk of reinfection was around 10 times higher in the period when the Omicron variant was most common (20 December 2021 to 20 March 2022),
compared with the period when the Delta variant was most common (17 May to 19 December 2021).
UK official data
REACT – 1 Round 19 (final round)
Community infection trends
RESULTS
In March 2022, prevalence was 6.37% (N=109,181),
more than twice that in February 2022
Lineages determined by viral genome sequencing
3,382 (99.97%) were Omicron,
346 (10.2%) BA.1, 3035 (89.7%) BA.2
one (0.03%) BA.3 sub-lineage
one (0.03%) was Delta AY.4
BA.2 Omicron sub-lineage had a growth rate advantage (compared to BA.1 and sub-lineages) of 0.11
Overall R=1.07
greatest increase in those aged 55+ years (R=1.12)
prevalence (in over 55s) on March 31, 2022 was 8.31%,
nearly 20-fold the median prevalence since May 1, 2020.
CONCLUSIONS
unprecedented levels of SARS-CoV-2 infection in England in March 2022
almost complete replacement of Omicron BA.1 by BA.2.
The high and increasing prevalence in older adults may increase hospitalizations and deaths,
despite high levels of vaccination.
(Funded by the Department of Health and Social Care in England.)
US data
Antibody Seroprevalence
Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories
43.3%
These percentages do not include people who have been vaccinated
and have no history of infection.
i.e. includes those vaccinated with a history of infection
Nationwide COVID-19 Infection- and Vaccination-Induced Antibody Seroprevalence (Blood donations)
Combined seroprevalence
94.7%
Infection induced seroprevalence
28.8%
Guests & Subjects Covered
Sentinel Indexing in Progress
Metadata and chapters are available. Claim extraction for this episode is pending.
All video content is delivered via YouTube embedded players in accordance with the YouTube Terms of Service. Sentinel provides research tools that promote discovery and accountability across political media.